- Tytuł:
-
Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage
breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up. - Autorzy:
- Źródło:
-
Thoracic
Cancer . Feb2024, Vol. 15 Issue 6, p439-447. 9p.
Czasopismo naukowe